Previous 10 | Next 10 |
- Well tolerated at doses up to 43 mg/m 2 with encouraging activity in heavily pre-treated patient populations - Favorable trend towards higher response rates with higher NaPi2b expression - On track for interim disclosure of Phase 1 expansion cohort data in Q2 2020 CAMBRIDGE, ...
Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVID-19 selloff. More news on: IDEAYA Biosciences, Inc., Surface Oncology, Inc., Jounce Thera...
CAMBRIDGE, Mass., March 20, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reaffirm...
Mersana Therapeutics, Inc. (MRSN) Q4 2019 Results Conference Call February 28, 2020 08:00 AM ET Company Participants Sarah Carmody - Executive Director, IR and Corporate Communications Anna Protopapas - CEO Brian DeSchuytner - SVP, Finance and Product Strategy Conference Call ...
Mersana Therapeutics ( MRSN ) Q4 results : More news on: Mersana Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Mersana Therapeutics (NASDAQ: MRSN ): Q4 GAAP EPS of -$0.34 beats by $0.04 . More news on: Mersana Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
XMT-1536 Phase 1 dose escalation data update selected for late-breaker oral presentation at upcoming Society of Gynecologic Oncology (SGO) 2020 Annual Meeting on Women’s Cancer XMT-1536 interim Phase 1 dose expansion data to be presented in 2Q 2020 with more mature data expecte...
Healthcare Pulse Source: Bloomberg The fear of Coronavirus (Covid-19) has infected the stock market. The market's patience completely ran out this week as the Coronavirus news, which has continued to weigh heavily on the negative side, sent the market reeling in a feral pullback. Wha...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 145 weeks of public selections as part of this ongoing live forward-testing. In...
CAMBRIDGE, Mass., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...